Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Return on Capital (ROC)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Return on Invested Capital (ROIC)

Eli Lilly & Co., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Invested capital2
Performance Ratio
ROIC3
Benchmarks
ROIC, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The period under review demonstrates significant fluctuations in Return on Invested Capital (ROIC). Initially, the ROIC experienced a decline, followed by a substantial increase over the observed timeframe.

Net Operating Profit After Taxes (NOPAT)
NOPAT decreased from US$5,065 million in 2021 to US$3,228 million in 2023, indicating a weakening in operational profitability. However, a dramatic recovery is evident, with NOPAT rising to US$8,605 million in 2024 and further increasing to US$19,711 million in 2025. This suggests a significant improvement in the company’s core earnings generation capability in the later years.
Invested Capital
Invested capital exhibited a moderate decrease from US$26,117 million in 2021 to US$24,287 million in 2022. Subsequently, it increased to US$29,370 million in 2023, and continued to rise, reaching US$35,786 million in 2024 and US$49,610 million in 2025. This upward trend suggests increasing investment in operations and growth initiatives.
Return on Invested Capital (ROIC)
ROIC began at 19.39% in 2021, declining to 17.98% in 2022 and reaching a low of 10.99% in 2023. This corresponded with the decrease in NOPAT. A substantial turnaround occurred in 2024, with ROIC increasing to 24.05%, and continued strongly into 2025, reaching 39.73%. This significant increase in ROIC indicates a markedly improved efficiency in generating profits from invested capital, driven by the substantial growth in NOPAT and continued investment.

The observed pattern suggests that while initial years experienced profitability challenges, the company demonstrated a strong ability to recover and significantly enhance its capital efficiency. The substantial increase in both NOPAT and invested capital, coupled with the dramatic rise in ROIC, points to successful strategic initiatives and improved operational performance in the later periods.


Decomposition of ROIC

Eli Lilly & Co., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2025 = × ×
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The period demonstrates significant fluctuations in return on invested capital (ROIC), driven by changes in operating profit margin, capital turnover, and the impact of the effective cash tax rate. An initial decline in ROIC is followed by substantial improvement over the observed timeframe.

Operating Profit Margin (OPM)
The operating profit margin exhibited volatility. It increased from 23.01% in 2021 to 25.19% in 2022, before decreasing to 20.50% in 2023. A strong recovery is then observed, with the margin rising to 30.09% in 2024 and reaching 40.98% in 2025. This suggests improving operational efficiency and/or pricing power in later years.
Turnover of Capital (TO)
Turnover of capital shows a consistent, albeit moderate, upward trend. Starting at 1.08 in 2021, it increased to 1.18 in 2022, 1.16 in 2023, 1.26 in 2024, and further to 1.31 in 2025. This indicates increasing efficiency in utilizing capital to generate revenue.
Effective Cash Tax Rate (CTR)
The factor (1 – Effective cash tax rate) decreased from 77.72% in 2021 to 60.75% in 2022, and then significantly to 46.15% in 2023. It partially recovered to 63.49% in 2024, and then increased substantially to 73.79% in 2025. This suggests changes in tax planning strategies or applicable tax laws, impacting after-tax profitability.
Return on Invested Capital (ROIC)
ROIC initially decreased from 19.39% in 2021 to 17.98% in 2022, and then experienced a more pronounced decline to 10.99% in 2023. A significant turnaround began in 2024, with ROIC increasing to 24.05%, and continuing strongly to 39.73% in 2025. The 2023 decline appears to be attributable to the combined effect of a lower operating profit margin and a reduced (1 – Effective cash tax rate). The subsequent recovery in 2024 and 2025 is largely driven by the substantial increase in operating profit margin, coupled with a rising (1 – Effective cash tax rate) and improving capital turnover.

The interplay between these components highlights the sensitivity of ROIC to changes in profitability, efficiency, and tax factors. The substantial improvement in ROIC in the later years suggests successful strategic initiatives focused on enhancing operational performance and managing tax liabilities.


Operating Profit Margin (OPM)

Eli Lilly & Co., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
 
Revenue
Profitability Ratio
OPM3
Benchmarks
OPM, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × ÷ =

4 Click competitor name to see calculations.


The operating profit margin exhibited a fluctuating trend over the five-year period. Initial increases were followed by a decline and then a substantial rise, indicating evolving profitability dynamics. Net operating profit before taxes also demonstrated a similar pattern, though with a more pronounced upward trajectory in later years.

Operating Profit Margin (OPM)
In 2021, the OPM stood at 23.01%. This increased to 25.19% in 2022, suggesting improved operational efficiency or pricing power. However, 2023 saw a decrease to 20.50%, potentially due to increased costs or competitive pressures. A significant recovery occurred in 2024, with the OPM rising to 30.09%, and this upward momentum continued into 2025, reaching 40.98%. This substantial increase in the OPM over the last two observed periods suggests a considerable improvement in the company’s ability to generate profit from its revenue.

The relationship between net operating profit before taxes and revenue appears to be strongly correlated with the OPM. While revenue increased consistently throughout the period, the growth in NOPBT was not uniform. The most significant increase in NOPBT occurred between 2023 and 2025, coinciding with the substantial rise in OPM. This suggests that improvements in operational profitability were a key driver of overall profit growth.

Revenue Growth & Profitability
Revenue increased from US$28,318 million in 2021 to US$65,179 million in 2025, representing a substantial overall growth rate. However, the OPM fluctuations indicate that revenue growth alone does not fully explain the changes in profitability. The significant jump in OPM from 20.50% in 2023 to 40.98% in 2025, alongside the revenue increase, demonstrates a period of amplified profit generation.

The observed trends suggest a potential shift in the company’s operational strategy or market conditions, leading to enhanced profitability in the later years of the observed period. Further investigation into the factors driving these changes, such as cost management initiatives, product mix shifts, or pricing strategies, would be beneficial.


Turnover of Capital (TO)

Eli Lilly & Co., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Revenue
Invested capital1
Efficiency Ratio
TO2
Benchmarks
TO, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Invested capital. See details »

2 2025 Calculation
TO = Revenue ÷ Invested capital
= ÷ =

3 Click competitor name to see calculations.


The period under review demonstrates a consistent upward trend in revenue, alongside fluctuations in invested capital, which subsequently impacts the turnover of capital. Revenue experienced growth across all observed periods, while invested capital exhibited initial decline followed by increases. This interplay directly influences the efficiency with which capital is utilized to generate sales.

Revenue
Revenue increased from US$28,318 million in 2021 to US$65,179 million in 2025. The growth was not linear, with a more substantial increase occurring between 2023 and 2025. This suggests accelerating sales performance in the latter part of the period.
Invested Capital
Invested capital decreased from US$26,117 million in 2021 to US$24,287 million in 2022, before increasing to US$49,610 million in 2025. The initial decrease may reflect efficiency gains or divestitures, while the subsequent increase likely corresponds to investments supporting revenue growth, potentially including research and development or capacity expansion.
Turnover of Capital (TO)
The turnover of capital ratio, which measures revenue generated per dollar of invested capital, generally increased from 1.08 in 2021 to 1.31 in 2025. While there was a slight decrease from 1.18 in 2022 to 1.16 in 2023, the overall trend is positive. This indicates improving efficiency in capital utilization. The increase in TO, coupled with rising revenue, suggests that investments are effectively translating into higher sales. The ratio’s peak in 2025 reinforces this observation.

In summary, the observed trends suggest a company successfully leveraging its invested capital to generate increasing revenue. The increasing turnover of capital ratio is a positive indicator of operational efficiency and effective capital allocation.


Effective Cash Tax Rate (CTR)

Eli Lilly & Co., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
Tax Rate
CTR3
Benchmarks
CTR, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =

4 Click competitor name to see calculations.


The effective cash tax rate exhibited considerable fluctuation over the five-year period. Cash operating taxes increased consistently year-over-year, while net operating profit before taxes (NOPBT) showed a more variable pattern. These movements significantly impacted the observed cash tax rate.

Effective Cash Tax Rate (CTR) - Trend Analysis
The effective cash tax rate began at 22.28% in 2021 and increased substantially to 39.25% in 2022. This increase coincided with a significant rise in cash operating taxes. The rate continued to climb, reaching a peak of 53.85% in 2023, despite a slight decrease in NOPBT. A notable decrease to 36.51% occurred in 2024, attributable to a much larger increase in NOPBT relative to the increase in cash operating taxes. The rate then declined further to 26.21% in 2025, as NOPBT experienced a substantial increase while cash operating taxes increased at a slower pace.

The relationship between cash operating taxes and NOPBT is crucial to understanding the CTR’s volatility. The substantial growth in NOPBT in 2024 and 2025 appears to have moderated the impact of increasing cash taxes on the overall effective tax rate. The peak in CTR in 2023 suggests a period where tax obligations grew at a faster rate than pre-tax profits.

Cash Operating Taxes - Trend Analysis
Cash operating taxes demonstrated a consistent upward trend throughout the period, increasing from US$1,452 million in 2021 to US$6,999 million in 2025. This represents a compounded annual growth rate of approximately 32.8%.
Net Operating Profit Before Taxes (NOPBT) - Trend Analysis
NOPBT experienced fluctuations. It increased from US$6,516 million in 2021 to US$7,190 million in 2022, then decreased slightly to US$6,996 million in 2023. A significant increase was observed in 2024, reaching US$13,553 million, followed by a further substantial increase to US$26,710 million in 2025. This growth in NOPBT, particularly in the later years, played a key role in moderating the effective cash tax rate.

The observed patterns suggest a dynamic tax situation, influenced by both changes in profitability and tax liabilities. Continued monitoring of these trends, alongside underlying drivers of both NOPBT and cash taxes, is warranted.